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a  b  s  t  r  a  c  t
TAK-448  is  a nonapeptide  analogue  and  a  novel  metastin  receptor  agonist.  The  aim  of this  study  was  to
develop  a bioanalytical  method  for TAK-448F  (the  free  base  of  TAK-448)  in  human  plasma  with  LC/MS/MS
that  is sensitive  and  applicable  for the  clinical  PK studies,  and  to  evaluate  the reliability  and  robustness  of
the developed  method  through  a validation  study  in accordance  with  the regulatory  guidance/guideline.
The  bioanalytical  method  developed  in this  study  can be  outlined  as  follows.  The  structural  analogue,
TAK-683,  was  used  as the  internal  standard  (IS).  TAK-448F  and  the  IS  were  extracted  from  human  plasma
using solid  phase  extraction  (SPE)  with  a polymer-based  weak  cationic  exchanger.  After  evaporating,
the  residue  was  reconstituted  and  injected  into  a LC–MS/MS  system  with  ESI probe  and  analyzed  byioanalysis
C–MS/MS
alidation
the  selected  reaction  monitoring  (SRM)  in the  positive  ion  mode.  Separation  was  performed  through  an
UPLC  BEH  Phenyl  column  with  the  mobile  phase  of  water/methanol/formic  acid  mixture  at  a  ﬂow  rate
of 0.2  mL/min.  The  total  run time  was  10 minutes.  The  LLOQ  was  achieved  to  be  5 pg/mL  with  0.5  mL
of  human  plasma  sample.  All the  validation  results  met  the acceptance  criteria  in  accordance  with  the
regulatory  guidance/guideline  proving  its  reliability  and  robustness.  As  a result  of  the  clinical  study,  the
human  PK  proﬁles  of TAK-448F  were  successfully  obtained  with  this  method.
 201©
. Introduction
Peptide drugs often have potent activity and are well known
s challenging drugs for the bioanalytical works due to the low
lasma concentrations at therapeutic dose levels [1,2]. Tradi-
ionally, immunoassays such as enzyme-linked immunosorbent
ssay (ELISA) and radioimmunoassay (RIA) have been employed
or the determination of peptides in biological samples [3]. These
ssays generally have high sensitivity and can provide high sample
hroughput although there are some inherent issues such as a
isk of cross-reactivity with structurally similar peptides including
etabolites and endogenous components, and requirement of the
peciﬁc antibody to an analyte. Other bioanalytical platforms such
s liquid chromatography (LC) with ultraviolet, ﬂuorescence and
lectrochemical detections have been reported for the quantita-
ive determination of peptides [4–6]. These methods have good
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linearity with wide calibration ranges and good repeatability but
have limited sensitivity and selectivity on the detection.
Recently, the bioanalysis of liquid chromatography tandem
mass spectrometry (LC/MS/MS) has become common not only for
small molecules but also for proteins and peptides [1,7]. Since
LC/MS/MS-based assays have certain advantages that it does not
require any speciﬁc materials such as antibodies, and most equip-
ment can be shared with the bioanalysis of small molecules, it
would be preferably chosen if there is no issue on the sensitiv-
ity. Thus, it should be critical if the sensitivity can be improved
on the LC/MS/MS-based assays of proteins and peptides. In most
cases, the sensitivity is largely inﬂuenced by the processes of elec-
trospray ionization (ESI) and collision induced dissociation (CID) in
addition to sample treatment procedures [2]. On the selected reac-
tion monitoring (SRM) analysis of proteins and peptides, a number
of ions with different charged states at ESI and various fragmenta-
tions at CID lead to reduction of the intensity. To overcome these
challenges, optimization of LC/MS/MS conditions should be more
carefully done compared to small molecules. The sensitive SRM
analyses for proteins and peptides have been reported by several
studies. Lovgren et al. and Zhang et al. reported highly sensitive
Open access under CC BY-NC-ND license.SRM analyses of peptides [8,9]. They improved the sensitivity by
optimizing all the conditions carefully and achieved the low LLOQs
which are almost equivalent to ELISA assays. Simon et al. demon-
strated that peptide signals on the SRM analysis were improved by
D license.
7 cal an
m
e
l
l
i
a
f
h
c
T
t
a
i
m
m
a
a
r
m
w
T
s
t
r
a
t
u
2
2
o
t
l
T
f
c
N
w
2
(
s
f
s
T
5
B
p
a
p
t
t
6
c
(6 Y. Kuze et al. / Journal of Pharmaceuti
odifying the charged status of peptides [10]. These reports have
ncouraged the use of LC/MS/MS for the bioanalysis of peptides.
TAK-448, 2-(N-Acetyl-d-tyrosyl-trans-4-hydroxy-l-prolyl-
-asparaginyl-l-threonyl-l-phenylalanyl)hydrazinocarbonyl-l-
eucyl-Nω-methyl-l-arginyl-l-tryptophanamide monoacetate,
s a nonapeptide analogue and a new oral metastin receptor
gonist discovered by Takeda and currently under development
or potential use in the treatment of prostate cancer [11]. TAK-448
as potent pharmacological activity with presumed effective
oncentrations at low levels in the pg/mL range in human plasma.
his suggests the need for a highly sensitive bioanalytical method
o monitor the drug concentrations in the clinical studies, and
lso the reliability and robustness as a regulated bioanalysis is
mperative.
In the previous study, the sandwich ELISA method for the deter-
ination of TAK-448 was established and validated [12]. This
ethod is highly sensitive with 3 pg/mL of the LLOQ in rat plasma,
lthough as inherent issues for ELISA methods, speciﬁc monoclonal
ntibodies are required and the calibration range is relatively nar-
ow (3–300 pg/mL) compared to general chromatographic assay
ethods resulting in the necessity of frequent dilution for samples
ith higher drug concentration.
The aim of this study was to develop a bioanalytical method for
AK-448 in human plasma based on an LC/MS/MS technology that
hould be highly sensitive with a sufﬁcient calibration range for
he use in the clinical studies, and to evaluate the reliability and
obustness of the developed method through a validation study in
ccordance with the regulatory guidance/guideline [13,14]. Addi-
ionally, human PK proﬁles in the phase I study were obtained by
sing the validated method.
. Material and methods
.1. Chemicals and reagents
The reference standard of TAK-448 and the internal standard (IS)
f TAK-683, 2-(N-Acetyl-d-tyrosyl-d-tryptophyl-l-asparaginyl-l-
hreonyl-l-phenylalanyl)hydrazinocarbonyl-l-leucyl-Nω-methyl-
-arginyl-l-tryptophanamide monoacetate were prepared by
akeda Pharmaceutical Company Limited. The chemical purity
or these standards was more than 90%. Blank human plasma
ontaining EDTA-2K as an anticoagulant was purchased from
ippon Bio-supp. Center. All the other chemicals and reagents
ere obtained from commercial sources.
.2. Instrumentation and conditions for LC/MS/MS analysis
The LC–MS/MS system consisted of an Acquity UPLC system
Waters Corp., MA,  USA) and an API5000 triple quadruple mass
pectrometer (AB Sciex, CA, USA) with a turbo ion spray inter-
ace. An Acquity UPLC BEH Phenyl (2.1 mm  I.D., 50 mm,  particle
ize 1.7 m,  Waters Corp.) was used for the HPLC column at 40 ◦C.
he following gradient was used: 0–0.5 min, B 5%; 0.5–1.2 min, B
–50%; 1.2–8.5 min, B 50%; 8.5–8.6 min, B 50–100%; 8.6–9.0 min,
 100%; 9.0–9.1 min, B 100–5%; 9.1–10.0 min, where the mobile
hase A and B were water/methanol/formic acid (900:100:1, v/v/v)
nd (100:900:1, v/v/v), respectively. The ﬂow rate of the mobile
hase was 0.2 mL/min from 0 to 8.6 min  and 0.4 mL/min from 8.6
o 10.0 min. The SRM with the positive ion mode was  used and
he monitoring ions (precursor ion → product ion) were set at m/z
14 → 511 for TAK-448F and m/z  650 → 545 for the IS. Instrument
ontrol and data analysis were performed with the Analyst software
version 1.4.1, AB Sciex).d Biomedical Analysis 83 (2013) 75– 81
2.3. Preparation of the stock solutions and standard/IS solutions
The stock solutions for TAK-448 and the IS were prepared
in water/methanol/formic acid (100:400:1, v/v/v) at a concen-
tration of 100 g/mL. The stock solutions were serially diluted
with water/methanol/formic acid (100:400:1, v/v/v) to prepare the
working solutions at appropriate concentrations and the IS solution
at 200 ng/mL.
2.4. Preparation of the calibration standards and quality control
(QC) samples
The calibration standards were ﬂeshly prepared for each batch
by adding the working solutions to the blank human plasma. The
concentrations in plasma for the calibration standards were 5, 20,
50, 200, 500, 2000, 5000 and 10,000 pg/mL. The QC samples were
prepared on the ﬁrst day in bulk by adding the working solutions to
the blank human plasma, and stored at −20 ◦C. The concentrations
in plasma for the QC samples were 5, 15, 400 and 8000 pg/mL.
2.5. Sample extraction procedure
A 500 L aliquot of each plasma sample was mixed with
500 L of a 500 mmol/L ammonium acetate–ammonia buffer (pH
7.0) and 10 L of the IS solution. The sample was loaded into a
solid phase extraction cartridge, OASIS WCX  (30 mg/1 cc, 30 m,
Waters Corp.), preconditioned with 1 mL of methanol and 1 mL
of distilled water. After the cartridge was washed with 1 mL  of
a 500 mmol/L ammonium acetate–ammonia buffer (pH 7.0) and
1 mL  of methanol, TAK-448F and the IS were eluted with 1 mL  of
a mixture of methanol/formic acid (98:2, v/v). The eluted solu-
tions were evaporated to dryness under a stream of nitrogen gas at
room temperature. The residues were reconstituted with 250 L of
a methanol/distilled water/formic acid (500:500:1, v/v/v) and 50 L
of the reconstituted solutions were injected into the LC–MS/MS
system.
2.6. Method validation
The developed method was  validated for the items of selec-
tivity, matrix effects, linearity of calibration curves, precision and
accuracy, recovery, stability in accordance with the regulatory
guidance/guideline [13,14].
2.6.1. Selectivity
Six lots of blank human plasma were analyzed without TAK-
448F and the IS, and the potential for interference peaks on the
SRM chromatograms was  visually evaluated. When an interfering
peak is detected at the eluting position of the analyte or the IS,
the response of the interfering peak should not exceed 20% of the
response of the analyte at the LLOQ or it should not exceed 5% of
the response of the IS.
2.6.2. Matrix effect
The matrix effect for TAK-448F was evaluated using 6 lots of
the blank human plasma. Six lots of the blank human plasma were
spiked with TAK-448F at the LQC level (15 pg/mL) and analyzed.
The accuracy of each sample calculated as the relative error to the
nominal concentrations (%RE) and the precision calculated as the
coefﬁcient of variation (%CV) were evaluated. The acceptance crite-
ria were set at within ±15% of the %RE and at <15% of the %CV,
respectively.2.6.3. Linearity of the calibration curves
The calibration standards at the concentration levels of 5, 20,
50, 200, 500, 2000, 5000 and 10,000 pg/mL were freshly prepared
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1Fig. 1. Chemical structures of the analyte, the free base of TAK-448 (T
nd analyzed on 3 different days. The calibration curves were ﬁt-
ed by weighted least-squares linear regression on the peak area
atios of the analyte to the IS versus the nominal concentrations of
he analyte: y = ax + b where y, x, a, b are the peak area ratio, the
ominal concentration, the slope and the y-intercept. The linear-
ty of the calibration curve was evaluated as the relative error of
he back-calculated concentrations to the nominal concentrations
%RE) and the correlation coefﬁcient of the calibration curves. The
cceptance criteria were set at within ±15% of the %RE except for
he LLOQ, where it should be within ±20%. At least 75% of the non-
ero standards or a minimum of seven non-zero standards should
eet the above, including the standards at the lowest and highest
oncentrations. The correlation coefﬁcient should not be less than
.995.
.6.4. Accuracy and precision
The accuracy and precision were evaluated using the spiked
amples at 4 concentration levels of 5 (the LLOQ), 15 (low), 400
medium) and 8000 (high) pg/mL. The spiked samples were ana-
yzed in 5 replicates on 3 different days. Intra- and inter-day assay
ccuracy was calculated as the relative error to the nominal concen-
rations (%RE). Intra- and inter-day assay precision was  calculated
s the coefﬁcient of variation (%CV). The acceptance criteria were
et at within ±15% of the %RE except for the LLOQ, where it should
e within ±20%, and at <15% of the %CV except for the LLOQ, where
t should be <20%.
.6.5. Recovery
The recovery was evaluated for TAK-448F at 3 concentration lev-
ls of 15, 400 and 8000 pg/mL and for the IS at a concentration level
f 4000 pg/mL. The peak area ratios obtained from the samples at
he above concentrations were compared with those of the spiked
amples after the extraction procedure.
.6.6. Stability
The sample stability of TAK-448F including on the bench-top
or 6 h, during 3 freeze/thaw cycles, post-preparative for 72 h and
ong-term for 12 months at −20 ◦C and −80 ◦C were investigated
sing the spiked samples at the 3 concentration levels of 15, 400
nd 8000 pg/mL. The sample stability was evaluated by the differ-
nce from the nominal concentration. For the solution stability, the
ench-top for 6 h and long-terms up to 6 months at 5 ◦C were inves-
igated. The solution stability was evaluated by the difference from
he initial peak area ratio. The acceptance criteria were set at within
00 ± 15% of the nominal or initial.48F) and the internal standard, the free base of TAK-683 (TAK-683F).
2.7. Clinical PK study
The bioanalytical method developed and validated here was
applied to the clinical PK study in which 3 healthy volunteers were
subcutaneously administered TAK-448 at doses of 0.001, 0.004,
0.01, 0.04, 0.1, 0.25 and 0.5 mg.  The study was approved the local
Ethics Committee and was carried out in accordance with the prin-
ciples of the declaration of Helsinki and the ICH guidelines. For
pharmacokinetic analysis, 5 mL  of blood samples were collected
at designated time points (0.083, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12,
16, 24, 36, 48 and 72 h postdose) and analyzed.
3. Results and discussion
3.1. Method development
For the development of the bioanalytical method for TAK-
448F, it was crucial that a low pg/mL level of the LLOQ would be
achieved with a minimum volume of human plasma. Addition-
ally, it would be preferable that the method be simple and high
throughput without any special equipment or techniques. To meet
these challenges, we focused on maximization of the S/N ratios on
the chromatograms through the optimization of the pretreatment
procedures and LC/MS/MS conditions.
For the internal standards, it is common knowledge that sta-
ble isotopically labeled (SIL) internal standards are preferable for
MS detection since they are chemically identical to the analytes;
however, SIL internal standards are not always available and then
structural analogues can be used with consideration of the struc-
tural similarities [15]. In the case of this study, we  decided trying to
use a structural nonapeptide analogue, TAK-683, for the IS because
preparation of the SIL internal standard for TAK-448 was  presum-
ably difﬁcult. As shown in Fig. 1, only one amino acid is different
between TAK-448 and TAK-683 in their structures. As a result, this
structural analogue worked well as the IS even though the reten-
tion times on the chromatograms were not identical. The successful
results should be due to high extraction recovery and low matrix
effects which lead to a similar behavior in the pretreatment proce-
dures and the MS  response.
A polymer-based weak cationic exchanger was  selected for the
solid phase extraction (SPE). Since the column has both weak cation
exchange and reversed phase properties, it is possible to elute
cationic analytes in cleaner conditions by optimizing a combina-
tion of wash and elute solvents in addition to its pH.  In this analysis,
the plasma samples were loaded onto the column and the column
was washed by the neutral buffer solution and methanol. Basic con-
ditions was avoided because of the limited stability of the analyte
and the IS. The analyte and the IS interacted well with the stationary
78 Y. Kuze et al. / Journal of Pharmaceutical and Biomedical Analysis 83 (2013) 75– 81
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hase and they were retained until the eluting solvent of methanol
ontaining formic acid was added.
Adsorption to plastic and glass surfaces is one of the major issues
n peptide analysis [1,2]. Actually, TAK-448F and the IS are adsorp-
ive to the surfaces of the containers in aqueous solutions and
his was a problem during the reconstitution procedures. How-
ver, it was found that adsorption of these two peptides can be
revented by adding a more than 50% volume of methanol to the
queous solutions. From this observation, a methanol/water/formic
cid (500:500:1, v/v/v) mixture was employed as the reconstitution
olvent. In the results of optimization of the pretreatment proce-
ures as mentioned above, high extraction recovery (>84%) was
chieved without any signiﬁcant matrix effects or interfering peaks
n the chromatograms.
On the mass spectrum of TAK-448F, the singly proton-
ted molecule ([M + H]+) and the doubly protonated molecule
[M + 2H]2+) were detected at m/z  1225.6 and m/z 613.6, respec-
ively. Additionally, the sodium adduct ion ([M + H + Na]2+) and the
otassium adduct ion ([M + H + K]2+) were detected at m/z 624.6 and
/z 632.5, respectively. The similar multiply charged ion peaks and
he similar adduct ion peaks are generally formed in peptide anal-
sis by ESI [2]. The doubly protonated molecule ([M + 2H]2+) had
igniﬁcantly higher intensity compared to the other molecules and
as selected as the precursor ion for the product ion scan anal-
sis. The product ion mass spectrum of the [M + 2H]2+ indicated
ome cleavages at the amide bonds which commonly occurs by
ID in peptides. As shown in Fig. 2, the y-series ions were mainly
etected although a few b-series ions were also detected. These
inds of cleavage are most typically observed in tandem MS  spectra
f peptides [2,16]. The ion of m/z 510.7, which was  presumed to be
ormed by loss of N-acetyl-d-tyrosyl moiety, was detected with the
ighest intensity on the product ion mass spectrum. As the result
f optimization for the SRM analysis, the monitoring transition for
AK-448F was set to be m/z 613.5 → m/z  511.0.
Fig. 3 shows SRM chromatograms of the blank (drug-free) sam-
le, the LLOQ sample (5 pg/mL) and the study sample around Tmax protonated molecule of TAK-448F ([M + 2H]2+).
(0.5 h postdose). The retention times of TAK-448F and the IS were
3.6–3.7 min  and 5.6–5.7 min, respectively. On the chromatograms
from the blank sample, no interfering peak was observed at the
retention time of TAK-448F. Around the retention time of the IS,
the baseline was  slightly lifted up and ragged but there was  no
impact on the quantitation since the IS peak was sufﬁciently high
compared to the baseline. As shown in Fig. 3(B) and (C), the TAK-
448F peak had enough sensitivity for quantitation of the LLOQ and
a good shape for integration of the study sample around Tmax.
Finally, the sensitive bioanalytical method with the wide cali-
bration range of 5–10,000 pg/mL was  established with LC/MS/MS.
The LLOQ level was almost comparable to that in the previously
established ELISA method [12].
3.2. Method validation
The developed bioanalytical method for TAK-448F in human
plasma was validated for its selectivity, matrix effects, linearity
of calibration curves, precision and accuracy, recovery, stability,
dilution integrity and the LLOQ.
3.2.1. Selectivity
No visible interference peak was observed at the retention time
of TAK-448F and there was no inter-individual difference on the
chromatograms from six lots of blank human plasma. As for the
chromatograms of the IS, the baseline was  slightly lifted up around
the retention time of the IS although it was at a negligible level for
the quatitation.
3.2.2. Matrix effects
Table 1 shows the results of the analysis of six lots of the human
plasma samples spiked with TAK-448F at the LQC level (15 pg/mL).
All the data from six individual plasma met  the acceptance criteria
and no signiﬁcant matrix effects were observed.
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Fig. 3. SRM chromatograms of TAK-448F and the IS from the blank sample (A), the LLOQ sample (5 pg/mL) (B) and the study sample at 0.5 h postdose (0.25 mg) (C).
Table 1
Matrix effect.
Blank plasma source Nominal conc. of TAK-448F (pg/mL) Observed conc. of TAK-448F (pg/mL) Mean ± SD (pg/mL) CV (%) RE (%)
Subject 1 (male) 16.5 10.0
Subject 2 (male) 14.8 −1.3
Subject 3 (male) 15.2 1.3
Subject 4 (female) 15 14.9 15.2 ± 0.7 4.6 −0.7
Subject 5 (female) 15.2 1.3
Subject 6 (female) 14.7 −2.0
Table 2
Calibration curves.
Nominal concentration of TAK-448F (pg/mL) Calculated concentration of TAK-448F (pg/mL) RE (%)
1st day 2nd day 3rd day 1st day 2nd day 3rd day
5 5.10 5.05 5.04 2.0 1.0 0.8
20  19.0 19.3 19.5 −5.0 −3.5 −2.5
50  48.2 49.1 48.7 −3.6 −1.8 −2.6
200  200 199 197 0.0 −0.5 −1.5
500  501 507 489 0.2 1.4 −2.2
2000  2010 2080 2060 0.5 4.0 3.0
5000  5220 5100 5210 4.4 2.0 4.2
10,000 10,300 9820 10,200 3.0 −1.8 2.0
Slope  0.000314 0.000328 0.000325
Y-intercept 0.00013 −0.0000634 −0.0000825
Correlation coefﬁcient 0.9995 0.9997 0.9996
Equation of calibration curve: y = ax + b, (weight: 1/y2)
x: nominal concentration, y: ratio of peak area, a: slope, b: y-intercept.
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Table 3
Accuracy and precision.
Assay day Concentration of TAK-448F (pg/mL)
Nominal 5 15 400 8000
1 Observed 4.40 14.2 415 8380
4.68  13.9 418 8510
4.64 14.2 421 8440
4.52 14.5 421 8600
4.86  13.7 416 8660
Mean  4.62 14.1 418 8520
SD  0.17 0.3 3 110
CV  (%) 3.7 2.1 0.7 1.3
RE  (%) −7.6 −6.0 4.5 6.5
2 Observed 5.09 13.0 381 7670
4.64  13.5 378 7720
4.74  13.7 378 7740
4.65  13.3 379 7620
5.04  13.6 374 7610
Mean  4.83 13.4 378 7670
SD  0.22 0.3 3 60
CV  (%) 4.6 2.2 0.8 0.8
RE  (%) −3.4 −10.7 −5.5 −4.1
3 Observed 5.69 14.8 382 8020
5.16  14.5 398 8000
5.41  13.9 391 7960
5.33  14.7 400 8000
4.93  14.5 391 8000
Mean  5.30 14.5 392 8000
SD  0.28 0.3 7 20
CV  (%) 5.3 2.1 1.8 0.3
RE  (%) 6.0 −3.3 −2.0 0.0
Mean  4.92 14.0 396 8060
SD  0.35 0.6 20 430
CV  (%) 7.1 4.3 5.1 5.3
3
l
p
1
r
v
w
3
l
(
a
o
r
3
3
T
S
MRE  (%) −1.6 
.2.3. Linearity of calibration curves
Table 2 shows the results of the calibration standards ﬁtted by a
inear regression with a weight of 1/y2 on 3 different days. As com-
ared to other weighting factors of 0 and 1/y, the weighting factor of
/y2 showed fairly constant %RE values throughout the calibration
ange with the smallest sum of the absolute %RE values. The %RE
alues ranged from −5.0% to 4.4% and the correlation coefﬁcients
ere within 0.9995–0.9997.
.2.4. Accuracy and precision
Table 3 shows the results of the QC samples at 4 concentration
evels analyzed in ﬁve replicates on 3 different days. The precision
%CV) and the accuracy (%RE) on each assay ranged from 0.3% to 5.3%
nd from −10.7% to 6.5%, respectively. The precision and accuracy
n inter-day assay ranged from 4.3% to 7.1% and from −6.7% to 0.8%,
espectively..2.5. Recovery
The recovery for TAK-448F ranged from 84.4% to 95.8% through
 concentration levels. The recovery for the IS was 93.3%.
able 4
tability of TAK-448F in human plasma.
Nominal conc. of TAK-448F (pg/mL) Observed conc. of TAK-448F (pg/mL) (Percenta
Initial Bench-top
for 6 h
Three f
cycles a
15 14.6 (97.3) 13.8 (92.0) 14.1
400  399 (99.8) 372 (93.0) 386 (9
8000  8490 (106.1) 7730 (96.6) 7870 (9
ean values (n = 3).−6.7 −1.0 0.8
3.2.6. Stability
Table 4 shows the results of the stability in human plasma.
TAK-448F in human plasma was  stable under the follow-
ing conditions; 3 freeze/thaw cycles, bench-top for 6 h, in a
freezer set at −20 ◦C and −80 ◦C for 12 months. Addition-
ally, TAK-448F in the post-preparative sample was  stable for
72 h.
The stock and standard solutions were stable on the bench-top
for 6 h and in a refrigerator set at 5 ◦C for 3 months.
3.3. Application
After the validation study was  completed, the method was
applied to the phase I clinical study. The plasma concentration-
time proﬁles of TAK-448F after a single subcutaneous injection
are shown in Fig. 4. Even at the lowest dose (0.001 mg),
the elimination phase of TAK-448F was  successfully obtained
up to 4 h. Almost all the samples were analyzed with-
out any dilution since the calibration range was  wide and
appropriate.
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standards in quantitative bioanalysis using liquid chromatography/mass spec-ig. 4. Plasma concentration-time proﬁles of TAK-448F in healthy male subjects
fter a single subcutaneous injection of TAK-448 (mean value, n = 3 each dose).
. Conclusions
The highly sensitive LC–MS/MS method for the nonapeptide,
AK-448F, in human plasma was developed and it was fully val-
dated in accordance with the regulatory guidance/guideline. The
LOQ was achieved to be 5 pg/mL with 0.5 mL  of human plasma
ample without any special equipments. The method was  applied
o the clinical study and the plasma concentration–time proﬁles
ere successfully obtained. This demonstrates the method is useful
or further clinical PK studies on the drug development.
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